Monday, November 02, 2015 11:46:40 AM
There was an article this summer in Seeking Alpha on SRNE before some of the latest deals and I think the author pegged it. He said, do not look at SRNE for its science but for its deal making and this was mainly for their deals with PSS. They seem to be acting more as an investment banker/venture capitalist/gold-silver streaming company all in one. I think they are going to sell off or JV the rights to the biosimilar/betters and retain royalty interests and the same could be said about many of the products in their pipeline. The new COO supposedly has lots of China ties and was surprised that SRNE was able to negotiate the deal for the 4 biosimilars and one of the reasons he went with them. At least one analyst thinks SRNE could sell the rights to the Remicade biobetter for $billions as it supposedly is the only one already in existence.
If the cell penetrating technology from City of Hope were to be proven to work, it would be worth many billions as it is the holy grail of biotech and every company would want the rights to it.
It is hard to see them missing on all of their bought deals, and they only need to hit on one of their potential blockbusters. jmho
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM